Oftalmol Zh. 2013;6:68-72.


Effect of recombinant erythropoietin on structural changes of the retina, hemoglobin concentration and erythrocytes quantity in peripheral blood in streptozotocin-induced diabetic rats

Pasyechnikova NV, Naumenko VA, Vit VV. Pilkevich TS

SI «The Filatov Institute of Eye Diseases and Tissue Therapy of NAMS of Ukraine»

Odessa, Ukraine

Introduction. Recently the role of erythropoietin (Epo) in the development of dia betic retinopathy has been studied.

Purpose. To determine the effect of recombinant erythropoietin (rEpo) on structural peculiarities of the retina, hemoglobin concentration and erythrocyte quantity in peripheral blood in streptozotocin-induced diabetes animals. 

Methods. 30 Vistar rats were included in the experiment. Diabetes was simulated using a single intraperitoneal injection of streptozotocin in a dose of 65 mgper 1 kg body weight. All rats were divided into three groups, each of 10 rats (20 eyes). Group 1 consisted of intact rats; group 2 — of streptozotocin-induced diabetes rats not receiving rEpo; group 3 — of streptozotocin-induced diabetes rats receiving rEpo. REpo administration started on the 10th day in a dose of 60 units per 1 kg of body weight three times a week during two weeks. 

Results. Epo was detected in peripheral blood and vitreous of intact rats. Erythrocyte quantity and hemoglobin concentration in blood didn't change in rats of Group 2. REpo administration in Group 3 led to significant increase of Epo concentration in peripheral blood and vitreous, increase of erythrocyte quantity and hemoglobin concentration. Development of retinal edema, vacuolar degeneration of retinal ganglion cells, signs of destructive changes in the retinal capillaries walls were noted in animals of Group 2, and rEpo administration significantly reduced the risk of development of those complications in Group 3.

Key-words: streptozotocin-induced diabetes, recombinant erythropoietin, diabetic retinopathy.


1.Chumayeva YeA. Ophthalmic consequences of diabetes: socio-sanitary and clinical aspects. Vestn Oftalmol. 2003; 5: 43-4. Russian.

2.BalaboHdn MI. Diabetology. M.: Meditsina; 2000. 672 p.

3.Starenka I. Treatment for diabetes: reality and prospects. Zdorovya Ukrainy. 2004; 3:24. Ukrainian.

4.Nesterov AP. Diabetic retinopathy. Russkii mezhdunarodnyi zhurnal. 2000; 1: 3-8. Russian.

5.Lovlya GD, Rudkovska OD, Golubovska NM, Pan-kiv VI. Frequency and risk factors of diabetic retinopathy in type 1 diabetes. Theses of symposia. Odessa, 2001: 173-4. Ukrainian.

6.Moshetova LK, Kasatkina EP, Saburova GSh, Ochiro-va EA, Borodai AV, Plastinina AM. Multifactorial etiology of diabetic angiopathy. Oftalmokhirurgiia. 2000; 4: 72-5. Russian.

7.Semenov AD, Malov VM, Branchevskii SL. Blindness in diabetic patients: medical and social aspects of the problem. Oftalmokhirurgiia. 1998; 4: 33-7. Russian.

8.Tronko ND, Orlenko VL. Proceedings of the 42nd Congress of the European Association for the Study of Diabetes. 2006; 21: 210-41.

9.Nesterov AP. Diabetic retinopathy. . Russkii mezhdunar-odnyi zhurnal. 2000; 1: 3-8. Russian.

10.Kolesnik YuM, Orlovskii MO, Kalinichenko MA, Greko-va TA. Modification of resistance to diabetic factors under the influence of chronic stress and adaptation to periodic hypoxia. Zaporozh Med Zhurn. 2005; 3: 21-6. Ukrainian.

11.Katsura Y, Okano T, Matsuno K et al. Erythropoietin Is Highly Elevated in Vitreous Fluid of Patients With Prolif-erative Diabetic Retinopathy. Diabetes Care. 2005; 28(9): 2252-4.
Crossref   Pubmed

12.Wang ZY, Zhao KK, Zhao PQ. Erythropoietin therapy for early diabetic retinopathy through its protective effects on retinal pericytes. Med. Hypotheses. 2011; 76(2): 266- 8.
Crossref   Pubmed

13.Buemi M, Cavallaro E, Floccari F et al. Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clinical. Science. 2002; 103: 275-82.
Crossref   Pubmed